NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Forecast, Price & News

$1.45

-0.11 (-7.05%)

(As of 09/20/2023 ET)

Compare

Today's Range: $1.44
▼
$1.58
50-Day Range: $1.45
▼
$3.35
52-Week Range: $1.44
▼
$8.25

Volume: 707,604 shs
Average Volume: 800,407 shs
Market Capitalization: $363.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.25

Lyell Immunopharma MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 331.0% Upside
$6.25 Price Target
Short Interest: Bearish
18.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.08) to ($1.19) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

727th out of 961 stocks

Pharmaceutical Preparations Industry

341st out of 454 stocks

3.1

Analyst's Opinion

Consensus Rating
Lyell Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.25, Lyell Immunopharma has a forecasted upside of 331.0% from its current price of $1.45.
Amount of Analyst Coverage
Lyell Immunopharma has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
18.27% of the float of Lyell Immunopharma has been sold short.
Short Interest Ratio / Days to Cover
Lyell Immunopharma has a short interest ratio ("days to cover") of 24.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Lyell Immunopharma has recently decreased by 3.67%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Lyell Immunopharma does not currently pay a dividend.
Dividend Growth
Lyell Immunopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LYEL.

0.6

News and Social Media Coverage

MarketBeat Follows
1 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.00% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
48.67% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lyell Immunopharma are expected to decrease in the coming year, from ($1.08) to ($1.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lyell Immunopharma is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lyell Immunopharma is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lyell Immunopharma has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

LYEL Price History

30 days | 90 days | 365 days | Advanced Chart

LYEL Stock News Headlines

September 11, 2023 | marketwatch.com

Lyell Immunopharma Shares Up 8% on Cellares Collaboration

September 11, 2023 | finance.yahoo.com

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

September 21, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

August 31, 2023 | finance.yahoo.com

Lyell Immunopharma to Participate in Upcoming Investor Conferences

August 29, 2023 | finance.yahoo.com

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

August 28, 2023 | msn.com

JP Morgan cuts Lyell to neutral, pending data for cell therapy platform

August 28, 2023 | msn.com

JP Morgan Downgrades Lyell Immunopharma (LYEL)

August 26, 2023 | msn.com

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

September 21, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

August 9, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Lyell Immunopharma (LYEL)

August 8, 2023 | finance.yahoo.com

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

July 6, 2023 | lse.co.uk

MaxCyte inks strategic platform license with Lyell Immunopharma

July 6, 2023 | finance.yahoo.com

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

July 5, 2023 | finance.yahoo.com

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

June 16, 2023 | finance.yahoo.com

Why Shares of Lyell Immunopharma Jumped This Week

June 7, 2023 | finance.yahoo.com

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

June 1, 2023 | finance.yahoo.com

Even after rising 12% this past week, Lyell Immunopharma (NASDAQ:LYEL) shareholders are still down 31% over the past year

May 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Lyell Immunopharma (LYEL) Buy Recommendation

May 5, 2023 | markets.businessinsider.com

Lyell Immunopharma (LYEL) Receives a Buy from H.C. Wainwright

May 4, 2023 | finance.yahoo.com

Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates

May 4, 2023 | msn.com

Lyell Immunopharma reports Q1 results

May 4, 2023 | finance.yahoo.com

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

April 17, 2023 | finance.yahoo.com

There's No Escaping Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Muted Revenues

April 13, 2023 | benzinga.com

TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics

March 27, 2023 | finance.yahoo.com

Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?

March 26, 2023 | finance.yahoo.com

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 47% stake

March 1, 2023 | finanznachrichten.de

Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

See More Headlines

Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Company Calendar

Last Earnings: 8/08/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LYEL
CUSIP: N/A
CIK: 1806952
Web: www.lyell.com
Phone: 650-695-0677
Fax: N/A
Employees: 274
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.25
High Stock Price Forecast: $9.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +331.0%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-183,120,000.00
Net Margins: -432.13%
Pretax Margin: -432.13%
Return on Equity: -26.40%
Return on Assets: -23.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.63
Quick Ratio: 17.63

Sales & Book Value

Annual Sales: $84.68 million
Price / Sales: 4.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.34 per share
Price / Book: 0.43

Miscellaneous

Outstanding Shares: 251,030,000
Free Float: 190,781,000
Market Cap: $363.99 million
Optionable: Not Optionable
Beta: -1.38

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Richard D. Klausner M.D. (Age 71)
Founder & Exec. Chairman
Comp: $80k

Dr. Lynn Seely M.D. (Age 64)
Ph.D., Pres, CEO & Director
Comp: $430.69k

Mr. Charles W. Newton (Age 52)
Chief Financial Officer
Comp: $1.72M

Mr. Stephen J. Hill (Age 53)
Chief Operating Officer
Comp: $1.04M

Dr. Gary Lee Ph.D. (Age 46)
Chief Scientific Officer
Comp: $639.91k

Ms. Elizabeth Homans (Age 57)
Consultant
Comp: $1.99M

Prof. Stanley R. Riddell M.D.
Founder & Scientific Advisor

Dr. Crystal L. Mackall M.D.
Founder & Scientific Advisor

Nellie Dillery
Director of Accounting

Ms. Ellen Rose
Sr. VP of Communications & Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LYEL Stock - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares.
View LYEL analyst ratings or view top-rated stocks.
What is Lyell Immunopharma's stock price forecast for 2023?: 4 brokerages have issued 1 year price targets for Lyell Immunopharma's shares. Their LYEL share price forecasts range from $4.00 to $9.00. On average, they predict the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 331.0% from the stock's current price.
View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts.
How have LYEL shares performed in 2023?: Lyell Immunopharma's stock was trading at $3.47 at the start of the year. Since then, LYEL shares have decreased by 58.2% and is now trading at $1.45.
View the best growth stocks for 2023 here.
When is Lyell Immunopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our LYEL earnings forecast.
How were Lyell Immunopharma's earnings last quarter?: Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.31 million. Lyell Immunopharma had a negative net margin of 432.13% and a negative trailing twelve-month return on equity of 26.40%.
When did Lyell Immunopharma IPO?: (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

What is Lyell Immunopharma's stock symbol?: Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."
Who are Lyell Immunopharma's major shareholders?: Lyell Immunopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.21%), Foresite Capital Management IV LLC (3.86%), State Street Corp (2.46%), Geode Capital Management LLC (1.34%), Northern Trust Corp (0.57%) and Charles Schwab Investment Management Inc. (0.46%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends.
How do I buy shares of Lyell Immunopharma?: Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lyell Immunopharma's stock price today?: One share of LYEL stock can currently be purchased for approximately $1.45.
How much money does Lyell Immunopharma make?: Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $363.99 million and generates $84.68 million in revenue each year. The company earns $-183,120,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.
How many employees does Lyell Immunopharma have?: The company employs 274 workers across the globe.
How can I contact Lyell Immunopharma?: The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com.

This page (NASDAQ:LYEL) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial